HIV

Findings add to the understanding of the challenges that people living with HIV face now that it is a more manageable, long-term condition.

If replicated in future studies, the findings have important implications for the millions of people living with HIV, many of which display signs of residual viral replication despite treatment.

Market research firm sees growth in sales for injectable therapies developed with an eye toward improving adherence. Sales in pre-exposure prophylaxis are also projected to increase.

The rapid implementation of telehealth viewed favorably by providers involved in HIV care yet there are conflicting results on how well it facilitates patient retention.

The findings suggest patients with HIV should be recategorized to "increased risk" when looking at COVID-19 underlying medical conditions.

A majority of participants reported a likelihood of using LAIs.

Expanding public health insurance may help curb the HIV epidemic.

There needs to be more support for those at a socioeconomic disadvantage.

Injectable treatments may start to replace daily pills.

Telehealth can help deliver PrEP to patients.

New research by shows how one of the major scientific breakthroughs of recent years might be used to eliminate HIV infection.

Dovato lets adults with HIV reduce the number of antiretroviral therapies they take, while maintaining efficacy and a high barrier to resistance comparable to tenofovir-based regimens.

Dr. David Ho, who developed the HIV cocktail, has isolated antibodies he says could be used to create treatments for COVID-19.

Gilead, Harvard infectious disease expert disagree

In an effort to end the HIV epidemic, President Trump announced a program to provide free HIV-prevention medication to the uninsured.

New tools can help to identify patients at a high risk for HIV but not using PrEP.

The pharmacy chain is offering free testing in partnership with Greater than AIDS

There is no cure for HIV, but with proper medical treatment, the disease can be controlled.